Gene · 8438
Papers1,865
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 1,865
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comparison of Homologous Recombination Repair Gene Next-Generation Sequencing Analysis in Patients With Metastatic Castration-Resistant Prostate Cancer Between Local and Central Laboratories in Korea. | Ann Lab Med | 2023 | 36045058 | PubTator, text mining | PubMed |
| Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. | Clin Cancer Res | 2023 | 36043882 | PubTator, text mining | PubMed |
| A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. | J Clin Oncol | 2023 | 35960902 | PubTator, text mining | PubMed |
| BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma. | Cancer Med | 2023 | 35778964 | PubTator, text mining | PubMed |
| Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). | J Clin Oncol | 2023 | 35737919 | PubTator, text mining | PubMed |
| Roles of homologous recombination in response to ionizing radiation-induced DNA damage. | Int J Radiat Biol | 2023 | 34283012 | PubTator, text mining | PubMed |
| Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers. | Cancer Innov | 2022 | 38089758 | PubTator, text mining | PubMed |
| Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. | Cancer Res Commun | 2022 | 36970052 | PubTator, text mining | PubMed |
| Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition. | Cancer Res Commun | 2022 | 36969741 | PubTator, text mining | PubMed |
Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy. | Front Immunol | 2022 | 36818471 | PubTator, text mining | PubMed |
| Extrachromosomal circular DNA in cancer drug resistance and its potential clinical implications. | Front Oncol | 2022 | 36793345 | PubTator, text mining | PubMed |
| Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer. | Front Oncol | 2022 | 36713553 | PubTator, text mining | PubMed |
| Case report: Clinical features and prognosis of two Infants with rhabdomyosarcoma of the tongue. | Front Oncol | 2022 | 36686750 | PubTator, text mining | PubMed |
| The Adaptability of Chromosomal Instability in Cancer Therapy and Resistance. | Int J Mol Sci | 2022 | 36613695 | PubTator, text mining | PubMed |
| Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can! | Cancers (Basel) | 2022 | 36612041 | PubTator, text mining | PubMed |
| Challenges in next generation sequencing of homology recombination repair genomic variants in prostate cancer: A nationwide survey and calibration project in China. | Prostate Int | 2022 | 36570645 | PubTator, text mining | PubMed |
| PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC? | Indian J Urol | 2022 | 36568449 | PubTator, text mining | PubMed |
| Snf2 Proteins Are Required to Generate Gamete Pronuclei in Tetrahymena thermophila. | Microorganisms | 2022 | 36557679 | PubTator, text mining | PubMed |
| Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. | Biomedicines | 2022 | 36551764 | PubTator, text mining | PubMed |
| CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. | J Exp Clin Cancer Res | 2022 | 36539830 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8438/papers?page=15